vax vax AN IAVI REPORT BULLETIN AIDS VACCINE TRIALS 2004: YEAR IN REVIEW This map depicts the clinical trials of preventive AIDS vaccines that began in 2004. For some of these trials additional sites will be added in 2005; the currently planned additional sites are represented here by dashed lines. For updated information or further details about a specific trial, please visit the IAVI Vaccine Trials Database (www.iavi.org/trialsdb). Please also e-mail any additions or comments to [email protected]. Abbreviations: ABL: Advanced BioScience Laboratories, Inc.; AlphaVax: AlphaVax Human Vaccines Inc.; ANRS: Agence Nationale de Recherche sur le SIDA; AVANT: AVANT Immunotherapeutics, Inc.; Aventis: Aventis Pasteur; Biovector SA: Biovector Therapeutics, SA; HVTN: HIV Vaccine Trials Network; IAVI: International AIDS Vaccine Initiative; IDT: Impfstoffwerk Dessau Tornau GmbH; NIAID: US National Institute Allergy and Infectious Diseases; Therion: Therion Biologics Corporation; UMMS: University of Massachusetts Medical School; VRC: Dale and Betty Bumpers Vaccine Research Center at the US National Institutes of Health; WRAIR: Walter Reed Army Institute of Research. MAP KEY TRIAL INFORMATION • Month — Countries Trial Number Phase, No. volunteers VACCINE (CLADE) TRIAL SPONSOR; MANUFACTURER VACCINE TYPE DNA Viral Vector Protein Subunit COLOR KEY Dark green denotes countries where trials are currently ongoing. Light green indicates countries where trials will soon begin. • April — USA N/A Phase I, 36 volunteers gag + 5 env DNA (A, B, C, E); 5 rgp120 (A, B, C, E) UMMS; ABL • January — Thailand, Brazil, Haiti, Puerto Rico (Later: Malawi) HVTN 050/Merck 018 Phase I, 435 volunteers MRKAd5 HIV-1 gag (B) NIAID; MERCK • February — Finland C060301 Phase I/II, 28 volunteers GTU-MultiHIV (B) FIT BIOTECH • April — USA HVTN 056 Phase I, 96 volunteers HIV CTL MEP (B) NIAID; WYETH • May — USA N/A Phase I, 18 volunteers LFn-p24 (B) NIAID, WRAIR; AVANT • May — USA VRC 006 (04-I-0172) Phase I, 36 volunteers VRC-HIVADV014-00-VP (B); VRC-HIVADV014-00-VP (A, B, C) NIAID; GENVEC • June — USA HVTN 042/ANRS VAC 19 Phase I/II, 174 volunteers LIPO-5 (B); ALVAC-HIV (vCP1452) (B) HVTN, ANRS; AVENTIS • July — France ANRS VAC 16 Phase I, 70 volunteers LIPO-4T (B) ANRS; BIOVECTOR SA • July — USA HVTN 055 Phase I, 150 volunteers TBC-M358 (MVA) (B); TBC-M335 (MVA) (B); TBC-F357 (FPV) (B); TBC-F349 (FPV) (B) NIAID; THERION • August — USA VRC 007 (04-I-0254) Phase I, 15 volunteers VRC-HIVDNA016-00-VP (A, B, C) NIAID/VRC; VICAL • September — France ANRS VAC 18 Phase II, 132 volunteers LIPO-5 (B) ANRS; AVENTIS • October — USA HVTN 059 Phase I, 96 volunteers AVX101 (VEE) gag (C) NIAID; ALPHAVAX • November — USA HVTN 057 (rollover from HVTN 052) Phase I, 70 volunteers VRC-HIVADV014-00-VP (A,B,C) NIAID/VRC; VICAL • December — USA (Later: Peru, Dominican Republic, Haiti, Puerto Rico, Australia, Canada) HVTN 502/Merck023 Phase IIb, 1500 volunteers MRKAd5 HIV-1 gag/pol/nef (B) HVTN, MERCK; MERCK • January 2005 — USA IAVI C002 Phase I, 48 volunteers ADMVA (C) IAVI; IDT
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
vaxvaxAN IAVI REPORT
BULLETIN
AIDS VACCINE TRIALS 2004:
YEAR IN REVIEWThis map depicts the clinical trials of preventive AIDS vaccines that began in 2004. For some of these trials additional sites will be added in 2005; the currentlyplanned additional sites are represented here by dashed lines. For updated information or further details about a specific trial, please visit the IAVI Vaccine TrialsDatabase (www.iavi.org/trialsdb). Please also e-mail any additions or comments to [email protected].
Abbreviations: ABL: Advanced BioScience Laboratories, Inc.; AlphaVax:AlphaVax Human Vaccines Inc.; ANRS: Agence Nationale de Recherche sur leSIDA; AVANT: AVANT Immunotherapeutics, Inc.; Aventis: Aventis Pasteur;Biovector SA: Biovector Therapeutics, SA; HVTN: HIV Vaccine Trials Network;IAVI: International AIDS Vaccine Initiative; IDT: Impfstoffwerk Dessau TornauGmbH; NIAID: US National Institute Allergy and Infectious Diseases; Therion:Therion Biologics Corporation; UMMS: University of Massachusetts MedicalSchool; VRC: Dale and Betty Bumpers Vaccine Research Center at the USNational Institutes of Health; WRAIR: Walter Reed Army Institute of Research.
MAP KEYTRIAL INFORMATION
• Month — CountriesTrial NumberPhase, No. volunteers VACCINE (CLADE)TRIAL SPONSOR; MANUFACTURER
VACCINE TYPE
DNA
Viral Vector
Protein Subunit
COLOR KEY
Dark green denotes countrieswhere trials are currently ongoing.
Light green indicates countrieswhere trials will soon begin.
• April — USAN/APhase I, 36 volunteersgag + 5 env DNA (A, B, C, E); 5 rgp120 (A, B, C, E)UMMS; ABL
• January — Thailand, Brazil, Haiti, Puerto Rico (Later: Malawi)
HVTN 050/Merck 018Phase I, 435 volunteersMRKAd5 HIV-1 gag (B)NIAID; MERCK
• February — FinlandC060301Phase I/II, 28 volunteersGTU-MultiHIV (B)FIT BIOTECH
• April — USAHVTN 056Phase I, 96 volunteersHIV CTL MEP (B)NIAID; WYETH
• May — USAN/APhase I, 18 volunteersLFn-p24 (B)NIAID, WRAIR; AVANT
• May — USAVRC 006 (04-I-0172)Phase I, 36 volunteersVRC-HIVADV014-00-VP (B); VRC-HIVADV014-00-VP (A, B, C)NIAID; GENVEC
• June — USAHVTN 042/ANRS VAC 19Phase I/II, 174 volunteersLIPO-5 (B); ALVAC-HIV (vCP1452) (B)HVTN, ANRS; AVENTIS
• July — FranceANRS VAC 16Phase I, 70 volunteersLIPO-4T (B)ANRS; BIOVECTOR SA
• July — USAHVTN 055Phase I, 150 volunteersTBC-M358 (MVA) (B); TBC-M335 (MVA) (B); TBC-F357 (FPV) (B); TBC-F349 (FPV) (B)NIAID; THERION
• August — USAVRC 007 (04-I-0254)Phase I, 15 volunteersVRC-HIVDNA016-00-VP (A, B, C)NIAID/VRC; VICAL
• September — FranceANRS VAC 18Phase II, 132 volunteersLIPO-5 (B)ANRS; AVENTIS
• October — USAHVTN 059Phase I, 96 volunteersAVX101 (VEE) gag (C)NIAID; ALPHAVAX
• November — USAHVTN 057 (rollover from HVTN 052)Phase I, 70 volunteersVRC-HIVADV014-00-VP (A,B,C)NIAID/VRC; VICAL
• December — USA (Later: Peru, Dominican Republic, Haiti, Puerto Rico, Australia, Canada)
HVTN 502/Merck023Phase IIb, 1500 volunteersMRKAd5 HIV-1 gag/pol/nef (B)HVTN, MERCK; MERCK
• January 2005 — USAIAVI C002Phase I, 48 volunteersADMVA (C)IAVI; IDT
Related Documents
